Our experts have written, co-written, and provided insights into hundreds of publications.
Tavi P, Korhonen T, Hänninen SL, Bruton JD, Lööf S, Simon A, Westerblad H. Myogenic skeletal muscle satellite cells communicate by tunnelling nanotubes. J Cell Physiol 2010; 223(2): 376-83.
Hänninen SL, Ronkainen JJ, Leskinen H, Tavi. Mitochondrial uncoupling downregulates calsequestrin expression and reduces SR Ca2+ stores in cardiomyocytes. Cardiovasc Res 2010; 88(1):75-82.
Ronkainen JJ, Hänninen SL, Korhonen T, Koivumäki JT, Skoumal R, Rautio S, Ronkainen Veli-Pekka, Tavi P. Ca2+-calmodulin-dependent protein kinase II represses cardiac transcription of the L-type calcium channel alpha(1C)-subunit gene (Cacna1c) by DREAM translocation. J Physiol 2011; 598(Pt 11): 2669-86.
Karppinen S, Rapila R, Mäkikallio K, Hänninen SL, Rysä J, Vuolteenaho O, Tavi P. Endothelin-1 signalling controls early embryonic heart rate in vitro and in vivo. Acta Physiol (Oxf) 2014; 210(2): 369-80.
Karppinen S, Rapila R, Naumenko N, Tuomainen T, Koivumäki JT, Hänninen SL, Korhonen T, Tavi P. Ca2+-activated K+ current is essential for maintaining excitability and gene transcription in early embryonic cardiomyocytes. Acta Physiol 2015; 215: 7-9.
Karppinen S, Hänninen SL, Rapila R, Tavi P. Sarcoplasmic reticulum Ca2+ -induced Ca2+ release regulates class IIa HDAC localization in mouse embryonic cardiomyocytes. Physiol Rep. 2018; 6(2):e13522.
Häggman-Laitila A, Salokekkilä P, Karki S. Integrative review of the evaluation of additional support programs for care leavers making the transition to adulthood. J Pediatr Nurs 2020;54:63-77.
Af Björkesten CG, Ilus T, Hallinen T, Soini E, et al. Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohort. Eur J Gastroenterol Hepatol 2020 (online ahead of print).
af Björkesten CG, Ilus T, Hallinen T, Soini E, et al. Objectively assessed disease activity during ustekinumab treatment in a nationwide real-life Crohn’s disease cohort. Journal of Crohn's and Colitis 2020;14 (Issue Supplement 1):S434–S435.
Väätäinen S. Diabetesriski, suurentunut paastoglukoosi ja heikentynyt glukoosinsieto ovat yhteydessä heikentyneeseen terveyteen liittyvään elämänlaatuun. Erikoislääkäri 2020;30(2):56-8.
Väätäinen S. Health Utility along the diabetes continuum, examination of utility values in impaired glucose metabolism using pre-scored multi-attribute utility instruments. Doctoral dissertation. Publications of the University of Eastern Finland. Dissertations in Health Sciences, no 555. Kuopio: University of Eastern Finland, 2020.
Kakkostyypin diabeteksen tutkija myöntää: "Terveiden elämäntapojen noudattaminen on haaste itsellenikin." Mediuutiset 2020;(18):13. Medipersoona: Väätäinen S.
Psoriaasi ja nivelpsoriaasi. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecimin ja Suomen Ihotautilääkäriyhdistyksen asettama työryhmä. Helsinki: Suomalainen Lääkäriseura Duodecim, 2020 (viitattu 4.8.2020). Asiantuntija: Soini E.
af Björkesten CG, Ilus T, Hallinen T, Soini E, et al. Real-life dosing patterns and concomitant drug use among ustekinumab-treated patients with Crohn’s disease. Digital Oral Poster (DOP) 26. Journal of Crohn's and Colitis 2020;14 (Issue Supplement 1):S066.
Väätäinen S, Soini E, et al. Alemtuzumab is a budget-saving alternative to fingolimod and natalizumab in the treatment of highly active relapsing-remitting multiple sclerosis. Dosis 2020;36(1):36-59.
Mankinen P, Lundström T, Soini E, et al. Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis. Adv Ther 2020;37 (2): 800-18.
Väätäinen S, Soini E, et al. Economic Value of Adjunctive Brivaracetam Treatment Strategy for Focal Onset Seizures in Finland. Adv Ther 2020; 37: 477-500.
Heiskanen J, Hartikainen J, Martikainen J, et al. Purchases of medical therapy recommended for coronary artery disease before and after elective revascularisation. Eur J Clin Pharmacol. 2020;76(1):81-88.
Väätäinen S, Soini E, et al. Cost-benefit predictions of the Virtual Hospital 2.0 digitalized secondary care path for women with endometriosis in Turku area and in Finland. eHealth2019 – International Conference 2019 & The 24th Finnish National Conference on Telemedicine and eHealth “Data-Driven Health”. Kuopio, Apr 2-3, 2019.
ISPOR Europe 2019 Conference Award Winner. PIH18: Predicted cost and capacity benefits of the digitalized secondary care path for women with endometriosis @ Virtual Hospital 2.0. Presenting Author: Erkki Soini, ESiOR Oy, Kuopio, 15, Finland.
Soini E, Väätäinen S. Kansainvälisten kustannusvaikuttavuustulosten siirrettävyys Suomeen: Rivaroksabaani ja varfariini eteisvärinän hoidossa. Best Practice Nordic - Diabetes ja sydänsairaudet 2019;7(27):12-15.
Kohti terveyttä edistävää Suomea 2030. StopDia – investointilaskurin tulosraportti. Sovellusversio 1.0.
StopDia-investointilaskuri tyypin 2 diabeteksen ehkäisyn terveystaloudellisten vaikutusten arviointiin. ESiOR Oy; application: Aug 21, 2019.
Soini E, Virtanen O, Väätäinen S, et al. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland. Adv Ther 2020; 37:3348–69.
Soini E. Tietoaltaat: Data-analytiikan, tiedon tuotannon ja terveystaloustulosten hyödyntäjän aarreaitta? eHealth2019 – International Conference 2019 & The 24th Finnish National Conference on Telemedicine and eHealth “Data-Driven Health”. Kuopio, Apr 2, 2019.
Väätäinen S, Soini E, et al. Cost-benefit evaluation of digital HealthyWeightHub: Virtual Hospital 2.0. eHealth2019 – International Conference 2019 & The 24th Finnish National Conference on Telemedicine and eHealth “Data-Driven Health”. Kuopio, Apr 2-3, 2019.
Soini E, Väätäinen S, et al. Digitalized secondary care services for insulin-dependent diabetes patients – Predictive cost-benefit analysis of Virtual Hospital 2.0 digital care path. eHealth2019 – International Conference 2019 & The 24th Finnish National Conference on Telemedicine and eHealth “Data-Driven Health”. Kuopio, Apr 2-3, 2019.
Hallinen T, Soini E, et al. Child placement costs and cost drivers: Isaacus Kuopio data lake project. eHealth2019 – International Conference 2019 & The 24th Finnish National Conference on Telemedicine and eHealth “Data-Driven Health”. Kuopio, Apr 2-3, 2019.
Eberl A, Hallinen T, af Björkesten C-G, Heikkinen M, Hirsi E, Kellokumpu M, Koskinen I, Moilanen V, Nielsen C, Nuutinen H, Suhonen U-M, Utriainen K, Vihriälä I, Soini E, et al. Ustekinumab for Crohn’s disease: a nationwide real-life observational cohort study from Finland. Journal of Crohn's and Colitis 2019;13(Supplement 1): S415–S416.
Purmonen T, Puolakka K, Mishra D, Gunda P, Martikainen J. Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland. Clinicoecon Outcomes Res 2019;11:159-168.